Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 2/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16611005 | 0.82 | S1PR1 (0.36) | S1PR1S1PR3PIK3R1PIK3CAMTOR | |
| SCHEMBL21933454 | 0.79 | AR (0.39) | S1PR1S1PR3PIK3R1PIK3CAMTOR | |
| SCHEMBL21929669 | 0.79 | AR (0.38) | S1PR1S1PR3PIK3R1PIK3CAMTOR | |
| SCHEMBL16727857 | 0.78 | S1PR1 (0.38) | S1PR1S1PR3PIK3R1PIK3CAMTOR | |
| SCHEMBL21929666 | 0.76 | PIK3CA (0.51) | PIK3R1PIK3CAMTOR | |
| SCHEMBL23140215 | 0.73 | PIK3CA (0.42) | S1PR1S1PR3PIK3R1PIK3CAMTOR | |
| SCHEMBL29113168 | 0.70 | PIK3CA (0.41) | S1PR1S1PR3PIK3R1PIK3CAMTOR | |
| SCHEMBL16731004 | 0.68 | S1PR1 (0.37) | S1PR1S1PR3KDRKDM4E | |
| SCHEMBL18373112 | 0.67 | PIK3CA (0.42) | S1PR1S1PR3PIK3R1PIK3CAMTOR | |
| SCHEMBL16622903 | 0.67 | PIK3CA (0.41) | S1PR1S1PR3PIK3R1PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214572-B2 | 7-site substituted pyrrole triazine compounds or pharmaceutically acceptable salts thereof, and preparation method thereof and uses thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-01-04 | — | — | US | disclosed |
| US-20200157110-A1 | 7-SITE SUBSTITUTED PYRROLE TRIAZINE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PREPARATION METHOD THEREOF AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11214572-B2 | 7-site substituted pyrrole triazine compounds or pharmaceutically acceptable salts thereof, and preparation method thereof and uses thereof | PIK3R5, JAK2, PIK3C3 | S1PR1 1487/4885S1PR3 1756/4885SPR 2209/4885 |
| US-20200157110-A1 | 7-SITE SUBSTITUTED PYRROLE TRIAZINE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PREPARATION METHOD THEREOF AND USES THEREOF | PIK3R5, JAK2, PIK3C3 | S1PR1 1487/4885S1PR3 1756/4885SPR 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.